GrÃ¼nenthal, Patheon Partner for Abuse-Deterrent FormulationsBy
Patheon has signed a strategic agreement with GrÃ¼nenthal, an independent, family-owned, research-based pharmaceutical group headquartered in Aachen, Germany to serve as its preferred development partner for its products made using GrÃ¼nenthal's abuse-deterrent formulation technology INTAC, the company’s technology designed to reduce the potential for abuse of controlled substances.
Patheon was selected to assist with the development of advanced INTAC-based products, including single-entity and fixed-dose combination solid oral dosage forms with immediate- and modified-release properties.
As part of the agreement, GrÃ¼nenthal has agreed to install specialized equipment in Patheon's Cincinnati manufacturing site. Through their partnership, GrÃ¼nenthal and Patheon will partner to offer new solutions to the broader pharmaceutical industry.